10080results about "Macromolecular non-active ingredients" patented technology

Embodiments of the present disclosure provide insulin formulations having a near neutral pH and improved pharmacokinetic / pharmacodynamic properties, and uses in insulin infusion devices that may provide extended infusion period up to 7-14 days. Also provided are systems for administering insulin, the system may include a first reservoir, a second reservoir, an insulin pump configured to administer contents of the first reservoir or the second reservoir, and one or more hardware processors in communication with the insulin pump.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention provides a preparation method of a novel recombinant humanized collagen hydrogel. The method comprises the following steps: recombinant humanized collagen and a dialdehyde crosslinking agent are subjected to a reaction, the concentration of the dialdehyde crosslinking agent is 0.01-0.25%, and the recombinant humanized collagen is one or more of recombinant humanized type II collagen, recombinant humanized type III collagen and recombinant humanized type XVII collagen, and the recombinant humanized collagen has a triple helix structure. The aldehydes cross-linking agent suitable for the recombinant humanized collagen, especially the recombinant humanized collagen with a triple helix structure, and the optimal reaction conditions are determined.

The invention discloses a near-infrared emission aggregation-induced emission organic photo-thermal molecule and a preparation method and application thereof, and belongs to the technical field of biomedicine, and the structure is shown as a formula I: # imgabs0 # (I), wherein R1, R2, R3, R4, R5 and R6 are independently selected from groups containing alkyl chains. The invention also provides a preparation method of the organic photo-thermal molecule and application of the organic photo-thermal molecule in preparation of multifunctional protein nanoparticles with near-infrared aggregation-induced emission. The near-infrared emission aggregation-induced emission organic photo-thermal molecule provided by the invention shows excellent near-infrared imaging effect and photo-thermal capability under laser irradiation, and the obtained near-infrared aggregation-induced emission multifunctional protein nano particle has excellent photo-thermal effect and imaging resolution, has excellent targeting to brain tumor, and has good application prospects in blood brain barrier crossing, brain tumor targeting and brain tumor targeting. And tumor killing, photothermal and ferroptosis combined treatment has practical medical significance, and is expected to be widely applied to the aspects of intelligent drug delivery and nano medical treatment.

The disclosure provides a method for systemic delivery of a therapeutically effective amount of epinephrine to a subject comprising orally administering dipivefrin or a dipivefrin salt to the subject. The disclosure also includes a method of treatment of a disease amenable to treatment by in vivo delivery of systemic epinephrine comprising administering dipivefrin or a dipivefrin salt to a subject in need of in vivo delivery of systemic epinephrine. The disease can be a respiratory disorder, anaphylaxis, cancer, or a microbial infection. The disclosure also includes dipivefrin or dipivefrin HCl orally dissolving tablets.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention relates to a high-activity recombinant XVII type collagen as well as a rapid preparation method and application thereof, and belongs to the technical field of bioengineering. The amino acid sequence of the high-activity recombinant XVII type collagen is as shown in SEQ ID NO. 1, and the nucleotide sequence of the high-activity recombinant XVII type collagen is as shown in SEQ ID NO. 2. The invention also provides a preparation method and application of the recombinant XVII type collagen. The high-activity recombinant XVII type collagen has good biological activity, has good effects of promoting cell adhesion, cell proliferation and cell migration, and can be compounded with other proteins to form raw materials of tissue engineering products, cosmetics, health care products or medicines. The high-activity recombinant XVII type collagen gene is integrated to different positions of a yeast genome through three different vectors, and the copy number of a target gene is increased, so that the expression quantity of the recombinant XVII type collagen is remarkably increased, and the yield of the high-activity recombinant XVII type collagen is effectively increased.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention provides a recombinant humanized III-type collagen with a triple helix structure and preparation and application thereof, and belongs to the technical field of protein engineering, the amino acid sequence of the recombinant humanized III-type collagen comprises n core units, n is an integer of 1 or greater than 1, and the amino acid sequence of each core unit is as shown in SEQ ID NO: 1; the invention also provides a construction method of the expression system and a preparation method of the recombinant humanized III-type collagen. The invention also provides practical industrial application according to the characteristics of the protein. The recombinant humanized III-type collagen provided by the invention is high in purity, good in stability and high in biological activity, and experiments show that the recombinant humanized III-type collagen has various biological activities of promoting cell proliferation and migration and the like.

The invention provides temperature and pH responsive hydrogel entrapped with chlorogenic acid lipidosome as well as a preparation method and application of the temperature and pH responsive hydrogel, and relates to the technical field of biology. The temperature and pH responsive hydrogel entrapping chlorogenic acid lipidosome contains chlorogenic acid lipidosome, phenylboronic acid grafted modified gelatin and dopamine grafted oxidized hyaluronic acid, the concentration of the phenylboronic acid grafted modified gelatin is 3-10 wt%, the concentration of the dopamine grafted oxidized hyaluronic acid is 3-10 wt%, and the concentration of chlorogenic acid is 1-20 [mu] M. The temperature and pH responsive hydrogel can effectively promote wound healing independently or in combination with blue light.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention relates to the technical field of biological pharmacy, and discloses a probiotic microcapsule with a function of improving intestinal microecology, which comprises the following components in percentage by weight: lactobacillus rhamnosus: each gram of formula contains 1010 CFU of lactobacillus rhamnosus; lactobacillus acidophilus: each gram of the formula contains 109 CFU; clostridium butyricum: each gram of the formula contains 108 CFU; 5%-8% of a nano sodium alginate-chitosan compound; 3%-5% of peptide nanoparticles; 2%-4% of a natural polymer intelligent response film; 3%-6% of arabinoxylan oligosaccharide; 4%-7% of resistant dextran; 2%-4% of lentinan; and 0.1%-0.3% of resveratrol. Through a double-layer or three-layer embedding technology of the nano sodium alginate-chitosan compound and the intelligent response polymer film, the tolerance of the probiotics in gastric acid and cholate environments is remarkably enhanced, and targeted release of the probiotics in small intestines and colon is ensured.

The present disclosure provides, in various embodiments, stable injectable particle suspensions of therapeutic biologics and hyaluronan degrading agents that permit administration without the need for resuspension. In particular, the compositions disclosed herein are highly concentrated, low-volume injectable particle suspensions that increase bioavailability of therapeutic biologics.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Disclosed herein is a preserved liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist, a cyclodextrin comprising hydroxypropyl substitutions and one or more preservatives. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; and cardiovascular diseases.

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug / cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.

The invention belongs to the technical field of protein engineering, and discloses a Brazilian sweet protein mutant and application thereof. According to the invention, lysine is used for replacing aspartic acid at the 29th site of Brazilian sweet protein, and / or arginine is used for replacing glutamic acid at the 36th site, and / or alanine is used for replacing aspartic acid at the 50th site, amino acid mutation at the sites is carried out to construct a Brazilian sweet protein mutant, and the Brazilian sweet protein mutant is subjected to heterologous expression in pichia pastoris GS115, so that the Brazilian sweet protein mutant is obtained. And carrying out sweetness performance evaluation on the expressed Brazilian sweet protein mutant. The sweetness property of the double mutant Asp29Lys-Asp50Ala protein is improved by 240% compared with the sweetness property of the Brazilian sweet protein before mutation.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

Provided herein are compositions that are useful in healing wounds and / or treating inflammatory skin conditions comprising (a) a copper-containing peptide; (b) an antioxidant; and (c) a cyclic oligosaccharide-based polymer, where the copper-containing peptide and the antioxidant form a complex. Further provided herein are methods for healing wounds and / or treating inflammatory skin conditions using the compositions of the disclosure.

The invention discloses a double-layer microneedle patch and a preparation method thereof.The preparation method of the double-layer microneedle patch comprises the following steps that firstly, 3D printing is conducted through polydimethylsiloxane, and a PDMS mold similar to a machining microneedle is obtained; dispersing the medicine into the sericin solution to serve as an outer layer solution; dispersing germanium nanoparticles into the polycaprolactone solution to obtain an inner layer solution; and finally, adding the outer-layer solution into the needle-shaped groove of the PDMS mold, so that the needle-shaped groove is filled with the outer-layer solution, drying, adding the inner-layer solution, drying, and demolding to obtain the double-layer microneedle patch. When the double-layer microneedle patch is used for drug delivery, drugs can be dissolved and released in a short time, the inner layer is polycaprolactone (PCL) carrying photo-thermal agent germanium nanoparticles, degradation is slow, a photo-thermal effect is generated under irradiation of 808nm near-infrared light, residual tumor cells are induced to die immunogenicity, an immune microenvironment is programmed in a time sequence, and the double-layer microneedle patch has the advantages of being high in sensitivity, high in sensitivity and good in stability. Postoperative recurrence and metastasis of tumors are efficiently inhibited, and meanwhile operative wound repair is promoted.

The invention belongs to the technical field of biomedical materials, and relates to ultrasonic response adhesion integrated hydrogel as well as a preparation method and application thereof, the hydrogel comprises a hydrogel matrix, an interface anchoring agent and a functional load component; the preparation method comprises the following steps: 1, preparing a hydrogel precursor solution, and preparing a hydrogel matrix into a solution; 2, carrying out mold molding or injection crosslinking on the solution prepared in the step 1 to form hydrogel; 3, preparing an interface anchoring agent solution, and dissolving or dispersing an interface anchoring agent in a solvent to prepare the interface anchoring agent solution; the ultrasonic responsive adhesive hydrogel platform provided by the invention can provide an efficient, controllable and universal solution for tissue adhesion, targeted therapy, wearable attachment and the like in a complex microenvironment, and is suitable for a plurality of clinical scenes such as chronic wound management, surgical postoperative closure, infection control, adhesive bioelectronic fixation, soft tissue engineering and the like.

The invention relates to a stable silk fibroin liquid condensation body, gel and a preparation method and application thereof, and belongs to the technical field of silk fibroin. The preparation method comprises the following steps: S1, dissolving silk fibroin in a lithium bromide solution, and then adding trypsin for incubation to obtain an enzyme-digested silk fibroin solution; and S2, performing low-temperature programmed centrifugal treatment including an induction stage, a nucleation stage and a liquid-liquid phase separation stage on the enzyme-digested silk fibroin solution, and cleaning to obtain the stable silk fibroin liquid-state aggregate, the method can reduce aggregate liquid drop aggregation and improve the particle size uniformity of the liquid drops.

The present disclosure provides a pharmaceutical composition that includes enclomiphene and pregnenolone, and pharmaceutical combinations and uses thereof. The present disclosure also provides a pharmaceutical combination that includes a selective estrogen receptor modulator and testosterone in a form suitable for oral administration, and uses thereof.

The invention discloses a CA9-targeted chimeric antigen receptor and application thereof, and belongs to the technical field of biological medicines. The CA9 targeting chimeric antigen receptor provided by the invention comprises a CD8 alpha leading signal peptide, an anti-CA9 single-chain variable fragment, a CD8 alpha hinge, a CD8 transmembrane structural domain and a CD3 zeta intracellular costimulatory signal transduction structural domain. According to the invention, an anti-CA9 single-chain variable fragment is used as an antigen binding structural domain to construct a chimeric antigen receptor (CAR) molecule, the macrophage expressing the anti-CA9CAR can realize specific targeting and phagocytosis killing of CA9 positive kidney cancer cells, and the constructed lipid nanoparticle delivery system can effectively transfer a gene expression vector, so that the gene expression vector can realize effective target site delivery, and the CA9 positive kidney cancer cells can be effectively targeted and killed. The constructed hydrogel-liposome combined drug delivery system has the performance of relieving toxic and side effects, controllable release and hemostasis.

The invention discloses a gynecological antibacterial gel containing a carbomer component, and belongs to the technical field of gynecological nursing materials. The gel is prepared from 0.5 to 5 percent of plant extract microcapsules, 0.5 to 3 percent of carbomer, 2 to 10 percent of glycerol, 0.1 to 1.5 percent of triethanol and the balance of purified water. The plant extract microcapsule is prepared by compounding methacrylated silk fibroin and a caffeic acid hyaluronic acid graft, has temperature responsiveness, can improve the adhesive force on the surface of vaginal mucosa, and realizes slow release of the plant extract; the caffeic acid catechol hydroxyl is chelated with silver ions, a nano-silver monodisperse layer is formed on the surface of the microcapsule, and the antibacterial activity is improved. The composite plant extract can inhibit bacteria, repair mucous membranes and maintain the acidic microenvironment of the vagina. When the gel is prepared, the problem that the swelling efficiency of carbomer is low is solved through glycerol pre-grinding, and triethanolamine is added in three times to form a gradient cross-linked network. The problems that traditional gel is unstable in viscosity, poor in mucous membrane adhesiveness and prone to damaging vagina micro-ecology are solved, the antibacterial effect is good, and preservation is stable.

The invention belongs to the technical field of biomedical materials, and particularly relates to adipose-derived mesenchymal stem cell loaded conductive hydrogel and a preparation method and application thereof, the preparation method comprises the following steps: step S1, after hyaluronic acid is subjected to oxidation treatment, dopamine is grafted to oxidized hyaluronic acid, and oxidized hyaluronic acid-dopamine is obtained; step S2, carrying out amination treatment on gelatin to obtain aminated gelatin; s3, mixing the oxidized hyaluronic acid-dopamine with the aminated gelatin, and carrying out Schiff base crosslinking, so as to obtain hydrogel; and step S4, loading the adipose tissue-derived stromal cells by using the hydrogel. Dopamine is grafted on an oxidized hyaluronic acid macromolecular chain through amidation reaction, the hydrophilicity and the electrical property of the macromolecular chain are improved, a catechol structure is provided to provide possibility for iron ion coordination, the tissue adhesion, the injectability, the mechanical property and the electrical conductivity of the hydrogel are improved, and the hydrogel can be applied to the field of biomedical materials. After being applied to a spinal cord injury rat model, the functional recovery can be promoted.

The invention discloses a vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions and a preparation method and application thereof, the vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions comprises three layers, namely a core layer, a middle layer and an outer layer from inside to outside in sequence; the core layer is formed by coating vitamin K2 with a zein-lac hydrophobic core, the middle layer is a pea protein-pectin electrostatic compound, and the outer layer is sodium alginate and chitosan double-network gel. The micro-capsule system provided by the invention can be tightly combined in a gastric acid environment after being orally taken, the release of active ingredients in the stomach is reduced, and then the micro-capsule system stays at intestinal mucosa for a long time and slowly releases contents, so that the functions of the micro-capsule system are slowly presented outside, the half-life period is prolonged, and the action effect is improved. Vitamin K2 directly or indirectly participates in and regulates various physiological processes related to health, and plays an important role in the aspects of maintaining bone health, preventing cardiovascular diseases, protecting nerves, improving metabolism and the like.